NCT07915609
A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score
Timeframe: Baseline and Week 52
Secondary (41)
Percent change from baseline in Body Weight
Change From Baseline in High-Sensitivity C-Reactive Protein
Change from baseline in WOMAC Physical Function Subscale score
Percentage of participants with ≥50% reduction in the WOMAC pain subscale score
Percentage of participants with ≥30% reduction in the WOMAC pain subscale score
Show 36 moreShow less
Proportion of participants with utilization of protocol specified pain medication during the washout period
Amount of protocol specified pain medication during the washout period
Change from baseline in WOMAC stiffness score
Change from baseline in WOMAC total score
Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score
Proportion of participants meeting OMERACT-OARSI
Change from baseline in Average Pain Intensity-Numerical Rating Score
Change from baseline in Worst Pain Intensity -Numerical Rating Score
Change from baseline in SF-36 domain scales and component summary scales
Change from baseline in Body Weight
Change from Baseline in Body Mass Index
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Number of Participants with Serious Adverse Events (SAE)
Number of Participants with AE leading to permanent discontinuation from study intervention or study
Number of Participants with Adverse Events of Special Interest (AESI)
Number of Participants with Clinical laboratory abnormalities
Change from baseline in timed walking distance at Week 52
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function
Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score
Change From Baseline in WPAI:GH Presenteeism Score
Change From Baseline in WPAI:GH Work Productivity Loss Score
Change From Baseline in WPAI:GH Activity Impairment Score
Change From Baseline in Systolic Blood Pressure (SBP)
Change From Baseline in Diastolic Blood Pressure (DBP)
Change From Baseline in Total Cholesterol
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Change from baseline in Non-HDL Cholesterol
Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Change from baseline in Triglycerides
Change from Baseline in HbA1c (%) (T2D participants only)
Arms and interventions
PlaceboPlacebo comparator
Placebo
Arm 1: Berobenatide Once WeeklyExperimental
Berobenatide Once Weekly
Arm 2: Berobenatide Once WeeklyExperimental
Berobenatide Once Weekly
Arm 3: Berobenatide Once WeeklyExperimental
Berobenatide Once Weekly
Drugs: Berobenatide, Placebo
Sites
4 sites in 1 country